What is already known about this topic? 118
All existing severe asthma registries in the world were either country or region specific. Most 119 importantly, none shared a common set of variables for data collection. This impedes data sharing and 120 subsequently disallows data pooling to conduct research with robust sample size. 121
What does this article add to our knowledge? 122 This paper depicts a systematic method of soliciting group consensus on a topic that entails a spectrum 123 of choices and viewpoints. 124
How does this study impact our current management guidelines? 125 enabling data interoperability. 133
Objectives: To create a standardised list of variables for the first international registry for severe asthma 134 via expert consensus. 135
Methods: A modified Delphi process was used to reach consensus on a minimum set of variables to 136 capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the 137 field of severe asthma research. The process consisted of three iterative rounds. In each round, all Delphi 138 panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR 139
Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi 140 administrator to all panel members at subsequent rounds. Finalisation of the core variable list was 141 facilitated by two face-to-face meetings. 142
Results: Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen 143 variables will allow severe asthma to be assessed against patient demographics and medical history, 144 patient-reported outcomes, diagnostic information and clinical characteristics. Physician-reported 145 outcomes such as non-adherence and information about treatment and management strategies will also 146 be recorded. 147
Conclusion: This is the first global attempt to generate an international severe asthma registry using a 148 common set of core variables to ensure that data collected across all participating countries are 149 standardised. 150 including asthma education, are aimed at achieving optimal disease control via minimisation of current 167 symptoms and prevention of acute exacerbations using a stepwise approach to medication (2). 168
Although most asthma patients have mild to moderate disease symptoms that may be well-controlled 169 with standard treatment, a smaller sub-population remains uncontrolled and/or suffers from severe 170 symptoms. The exact prevalence of severe asthma is uncertain but has been estimated at 5−10% of the 171 asthma population (3-5). Such patients remain inadequately managed with the current standard of care 172
(3), which includes high-dose inhaled corticosteroids with additional controllers and represent a 173 significant unmet need. 174
There is compelling evidence to suggest that better standardised care for severe asthma is needed, 175
including the registration of systematic assessment and improved and aligned registries of patients 176 whose symptoms fulfil the criteria for severe asthma (6). Indeed, registries are well established tools 177 for tracking and reporting on the epidemiological attributes of a disease. They are valuable resources 178 which enable treatment benefits and risks to be proactively monitored over time, through the collection 179 of natural history data, and which aid the development of therapeutics and/or diagnostics. They can be 180 used to gather information on disease progression and patient subgroups, facilitate patient recruitment 181 into clinical trials, and generate real world evidence on the safety and cost effectiveness of new 182 therapeutics (7). Notably, registries are increasingly required as part of the post-approval safety 183 monitoring process of regulatory bodies for new treatments (7) . 184
The current registry landscape for severe asthma is viewed as a collection of divergent, national and 185 regional registries. The design, development and maintenance of such registries has typically revolved 186 around specific data collection platforms and drugs, leading to the creation of segregated systems with 187 little or no collaboration between the different collections. Individual registries have limited power due 188 to the relative rarity of severe asthma and stringent inclusion criteria. Different objectives and 189 governance rules also exist across different countries and/or organisations. These disparities can lead to 190 country-specific registries collecting different data fields of various quality. These limitations lead to 191 the implementation of only a subset of registry functions, resulting in the collection and analysis of 192 limited data on severe asthma. Pooling data across multiple registries will improve the precision of 193 incidence estimates, aid in identifying rare safety signals, and facilitate the exploration of possible drug-194 demographic, drug-disease or drug-drug interactions in different sub-populations of the combined 195 global severe asthma patients (8). To date, several national and regional severe asthma registries exist 196 (9-12), but none has an agreed international focus and standard list of data fields. 197
Using long-standing severe asthma registries from the United Kingdom (UK) (9) and Australia (11, 13), 198 our aim was to gain expert consensus on a standardised list of variables on demographic, clinical 199 characteristics, treatment and comorbidities to establish the first international registry for severe asthma 200 so that data can be seamlessly exchanged between countries and institutions without system-specific 201 differences. 202 203
Methods

204
This study utilised a modified, 3-round Delphi method process (14) to select the common core variables 205 to be collected in the International Severe Asthma Registry (ISAR). Variables were initially selected 206 from previously existing national severe asthma registries. This helped to hasten the process of building 207 the registry data collection framework by integrating real-world data elements that have been tested for 208 feasibility of usage and collection. 209
Panel selection 210
To achieve consensus, it was essential for the Delphi panel to include appropriately qualified and 211 experienced individuals who could provide critical and discrete input toward the issue. The ISAR 212
Delphi panel consisted of 27 experts in the field of severe asthma research. The panel members were 213 invited from 16 different countries ( Supplementary Table 1 ), and were selected according to two or 214 more of the following criteria: Delphi R1
235
The Delphi workbook (The ISAR Delphi Workbook Round 1) was developed by consolidating the 236 variable lists for the British (British Thoracic Society (BTS) Difficult Asthma Network) (9) and the 237 Australian (Severe Asthma Web-based Database (SAWD)) (13) severe asthma registry. These variables 238 were chosen as the initial bank of variables due to 15 years of usage and SAWD having the most number 239 of variables amongst the existing severe asthma registries as of 2017. However, as there were 907 240 variables in both registries combined, and given that there are limited resources available for data 241 collection, this exercise set out to determine not only the most appropriate variables but also to ensure 242 that data collection for such variables can be sustained in a clinical setting. 243
Information from both registries was formally requested and extracted to develop two sets of variables: 244 there were 115 variables in the "potential core" list (variables common to both registries; please see 245 Table 1 for a sample) and 632 variables in the "suggest" list (variables unique to either registry; please 246 see Table 2 for a sample). 247
The workbook was developed using Microsoft Excel 2016 MSO (V16.0) and consisted of a two-tab 248 spreadsheet with response-controlled questionnaires. On tab one, displaying the potential core list 249 (Table 1) , panel members were required to select an option ("Yes" or "No") via a drop-down menu for 250 each variable, indicating whether they concur that the variable would be part of the ISAR core variable 251 list. Panel members were also encouraged to nominate variables from the suggest variable list ( Table  252 2) on tab two and/or propose new variables. Experts were also encouraged to provide comments for 253 excluding or including variables. 254
The Delphi workbook was sent to each Delphi panel member electronically, to be completed 255 independently and returned via email to the Delphi administrator. At round closure, the Delphi 256 administrator anonymised all returned workbooks and compiled all replies to tabulate frequency of 257 responses, "Yes" and "No", for each variable on the lists. 258
Variable consensus was then evaluated using summary statistics (frequency counts) generated with a 259 statistical program (Stata 14, StataCorp LLC, Texas, USA). Each "potential core" variable that received 260 a majority (66.6%) or more consensus from the Delphi panel was selected as an ISAR core variable. 261 However, with the first-round of results, to exercise rigorous oversight, only variables with 100% 262 consensus were added to the core list. Variables with less than 50% consensus were reviewed and 263 removed. All other potential core variables were circulated for another round of review (Delphi R2). In 264 tandem to the potential core, the suggest list of variables was also reviewed to evaluate the number of 265 votes by the Delphi panel. Variables with at least two "Yes" votes were then circulated for another 266 round of review (Delphi R2). The Delphi R1 results were presented to the ISC (much of the Delphi 267 panel consisted of ISC members (22/27)) during the inaugural ISAR Steering Committee meeting in 268
March 2017. 269
Delphi R2
270 As in R1, the expert panel was requested to engage in a similar voting process for the Delphi R2 via a 271 limited-response electronic questionnaire (The ISAR Delphi Workbook Round 2). The Delphi R1 272 summary results and panel member comments ("Reasons") were anonymised and provided in the R2 273 workbook to facilitate an informed decision. Moreover, "Additional Information" on the use or 274 functionality of these variables in the ISAR registry was provided to aid panel members in their 275 decision. Potential core variables with less than 100% and greater than 50% consensus from R1 were 276 included in the R2 workbook. Additionally, suggest variables with at least two or more votes by Delphi 277 panel members were disseminated for a full panel poll in R2. 278
Delphi R3
279
The Delphi panel also took part in R3 via a limited-response electronic questionnaire (The ISAR Delphi 280 Workbook Round 3). Suggest variables and potential core variables were vetted concurrently in the 281 same manner in R3, following finalisation of suggest variables during R3 discussions by the Delphi 282 panel. Suggest variables from R2 which had attained more than 50% consensus and potential core 283 variables from R2 on which a consensus was not reached (>50% and <66.6% consensus) were circulated 284 for another round (R3). In addition, due to high relatability, nine of the suggest variables from R2 were 285 consolidated into four variables/questions after discussion at the inaugural Steering Committee meeting. 286
These were: current occupation, age at start of asthma symptoms, environmental allergen test 287 conducted, and current clinical management plan. These variables were added to the R3 workbook to 288 ensure full vetting and review by the panel. 289
The ISAR core variables were finalised during the second ISAR Research Prioritisation meeting in May 290 2017. R3 results and all outstanding concerns raised by panel members, such as data field options for 291 variables including ethnicity and occupation, were discussed and resolved at the second Steering 292
Committee face-to-face meeting. The participants were requested to re-evaluate the remaining five 293 undecided variables to arrive at a consensus on which variables would be submitted for another Delphi 294 round and hence, which would be retained or removed from the final ISAR core variable list. The Case Report Form (CRF). All chosen core variables were represented in the final CRF questionnaire 299 format. 300
All variables that were not selected for the core list at the end of the Delphi process were compiled 301 into a separate list. This list later gave rise to standard bolt-on variables, named "research variables". 302
Research variables are available to be adopted by a participating country-specific registry according to 303 local research interests and capacity to collect and store data. A participating country is encouraged to 304 add variables outside the core list to the country-specific registry, including and/or beyond the 305 
Results
321
Delphi R1
322
Fifteen of the 27 members of the panel participated in Delphi R1 (55.6%); 28 of 115 initial potential 323 core variables achieved complete consensus with 100% agreement for inclusion into the ISAR core 324 variable list. Eighty of the remaining variables received greater than 66.6% and less than 100% 325 consensus, six were undecided (50−66.6%) and one variable did not achieve consensus (<50%) 326
( Supplementary Table 2 ). A total of 86 potential core variables (less than complete consensus (80) and 327 undecided (6) variables)) were fed into the second round of the Delphi process. 328
Additionally, 54 suggest variables had attained at least two or more votes by the Delphi panel and 329 moved on to the second round of the Delphi process (R2) (Supplementary Table 2 ). The remaining 578 330 suggest variables were then appropriately reviewed and removed from the Delphi process. 331
Potential core variables with undecided consensus were: the GINA (Global Initiative for Asthma) 332 asthma control questionnaire and patient status as a research subject. The asthma medication question 333 regarding anti-leukotriene level received less than 50% consensus and was removed from the ISAR 334 potential core variable list and the Delphi review process after assessment by the Delphi neutral 335 facilitator. 336
Delphi R2
337 Thirteen panel members participated in R2 (48%). Eighty-six (less than complete consensus (80) and 338 undecided (6) variables) potential core variables were considered in R2. Of them, 74 achieved 339 consensus with more than 66.6% agreement for inclusion into the ISAR core variable list. Of the 340 remaining variables, eight were undecided and four did not achieve consensus. In addition, nine of 54 341 variables in the suggest variable list attained more than 66.6% agreement for inclusion into the ISAR 342 core variable list ( Supplementary Table 3 ). 
Delphi R3
359 Fourteen Delphi members participated in R3 (51.9%). Four of 12 R3 potential core variables achieved 360 consensus with more than 66.6% agreement for inclusion into the ISAR core variable list 361
( Supplementary Table 4 ). Of the remaining eight variables, five were undecided, and three did not 362 achieve consensus. Upon review by the Delphi neutral facilitator, and a face-to-face discussion with the 363 Steering Committee in May 2017, one undecided variable was included into the core variable list. All 364 three non-consensus variables and remaining four undecided variables were removed from the core list. 365 R3 resulted in five variables added to the core variable list. With all "potential core" variables achieving 366 a status of consensus or non-consensus, the Delphi exercise ended at R3. 367
To further streamline the process, undecided variables and non-consensus variables such as asthma 368 medication devices, prior clinical management plan, adverse events and comorbidities (Ischaemic Heart 369
Disease and Heart Failure) were removed from the core variable list. Date of bone densitometry was 370 added to the core list after ISC discussion, despite the undecided status. Step 4 treatments (3). Patients were considered to have uncontrolled asthma were defined as those 377 having severe asthma symptoms, consisting of poor symptom control, airflow limitation, or serious 378 exacerbations as per the ERS/ATS guidelines, or suffering exacerbations requiring two or more courses 379 of oral corticosteroids. 380
The overall results from the Delphi process are summarised in Figure 2 . 381
Final ISAR core variable list 382
The core variables that achieved consensus via the closely guided three rounds of Delphi were included 383 in the final core variable list (Table 3 ). The final ISAR core variable list consists of 95 variables, 83 384 variables that require data entry and 12 variables that do not require data entry (auto-populated). These 385 variables are classified into 13 variable categories. 386
The core variables were reported in a CRF, which allowed a probing mechanism to take place with a 387 branched questionnaire. A CRF was constructed to facilitate the process of data collection with 388 enhanced clarity. 389 390
Discussion
391
The aim of this Delphi-based study was to reach consensus among specialists in the field of severe 392 asthma on a core set of data fields to include in the International Severe Asthma Registry. Using the 393 knowledge and experience of an international panel of severe asthma experts, workable criteria for 394 registry purposes, a core set of variables and a potential method to unify data for severe asthma from 395 across the globe were generated. Analyses of these registry data will facilitate insight into this 396 heterogeneous disease on a global scale. All potential variables underwent a rigorous, stepwise 397 consensus process to ensure the collection of the minimum required information to effectively study 398 the development, therapeutics and management of patients with severe asthma. 399
Definitions, such as severe asthma, were based on expert opinion and precedence of use, because 400
achieving consensus of what constituted severe asthma at an early stage in the process was important. 401
The inclusion criteria, patients on GINA Step 5 therapy or uncontrolled on Step 4 therapy, were agreed 402 upon by a majority of the panel to ensure the inclusion of severe asthma patients in a real-world setting. 403
These criteria served the primary purpose of the registry to prospectively survey severe asthma patients. 404
In addition, the inclusion criteria allowed the core data to be used for broader purposes (e.g. uncontrolled 405 asthma etc.). The ISAR is not intended to assess the validity of real-life clinical practice, but merely to 406 observe the evolving patterns of clinical care to ultimately evaluate its safety and/or effectiveness in 407 order to improve the lives of patients. As such, no confirmation of asthma is required for enrolled 408
subjects. 409
Of the initially circulated potential core and suggest variables, 95 variables achieved Delphi panel 410 consensus. These variables represented 13 categories pertaining to the assessment and treatment of 411 patients with severe asthma. Each category will serve to collect subsets of information essential for a 412 more complete understanding of the disease. The successful limitation of core variables to less than 100 413 has resulted in an applicable CRF with a relatively small data entry burden for healthcare professionals 414 who are participating in the registry. The specific domains that will enhance global registry recruitment 415 and utility are discussed below. 416
Patient details and medical history 417
Patient demographic and medical history data fields will allow patients to be categorised (16). The 418 panel-approved variables were chosen to ensure a comprehensive set of patient characteristics are 419 collected for patient aggregation. Previous studies have shown that many patients overestimate their 420 level of asthma control and underestimate the severity of their condition, indicating that they tolerate 421 symptoms and lifestyle limitations (17) (18) (19) . The GINA questionnaire was the preferred tool for this 422 assessment, because previous studies have shown that it does not overestimate the proportion of patients 423 with controlled asthma and is therefore more likely to give a less exaggerated score compared to other 424 available questionnaires (20) . 425
Diagnostics 426
The expert panel agreed to collect screening and diagnostic results to help identify the care requirements 427 of individual patients. Biomarkers such as peripheral blood and sputum eosinophils, and fractional 428 exhaled nitric oxide (FENO) have been shown to be useful for the management of asthma (21, 22) , and 429 may help identify specific subtypes of severe asthma likely to benefit from treatment with novel 430 biological agents. 431
Adherence and comorbidities 432
Non-adherence to therapy is approximately 50% in adults with severe asthma (23-25). Physicians need 433 to ensure that patients are satisfied with their medication to increase adherence and optimise disease 434 control (26). The potential for ISAR to investigate non-adherence across different geographical regions, 435 with likely different healthcare systems, availability of medications and access to specialists and asthma 436 education, was noted. 437
A real-life study on asthma control reported that physicians believed that the main reasons for lack of 438 asthma control included comorbidities, as seen in 36.2% of patients, continued exposure to 439 irritants/triggers in 34.0% of patients, and inadequate adherence to treatment in 27.0% of patients (27) . 440
Treatment management plan 441
Asthma patient management practices among adults have been found to be inadequate in many practices 442 in Europe (28). Along with the information that ISAR will collect on clinical outcomes and 443 demographic characteristics, the best treatment management plan by patient group will be assessed. 444
Moreover, the panel agreed to collect broad treatment options to ensure that all participating countries 445 will be able to contribute without subjection to individual country specifications. 446
Strengths and weaknesses 447
The Delphi panel was composed of international severe asthma professionals to ensure that 448 recommendations recognised and reflected all social nuances specific to the participating countries 449 while maintaining applicability in more than one healthcare setting and location. Eighteen unique 450 Delphi panel members from 16 different countries participated in one or more Delphi rounds. This 451 allowed broad consensus to be obtained. Using a group approach ensured that more comprehensive 452 expertise was extrapolated than from any individual member alone. The selected panel of experts were 453 chosen not only for their expertise in the research field, but also for their relevant medical practice and 454 experience with developing and/or managing databases or regional/national severe asthma registries. 455
The Delphi method ensured versatility of application and enhanced the sustainability of ISAR in the 456 field due to panel members' involvement and cooperation in the generation of the registry data 457 specification. 458
The anonymity of the survey helped to reduce the influence of dominant individuals which may become 459 apparent during face-to-face meetings. However, the anonymity may also have reduced the positive 460 effects of interaction during face-to-face meetings, depriving experts of important exchanges of 461 information which would help to identify and discuss reasons for disagreement (29). The modified 462
Delphi process maximised the benefits of both consensus methods through the initial collection of 463 information via questionnaires followed by structured in-person meetings. ISAR meetings were 464 organised to allow panel and/or steering committee members to discuss variables and selection criteria 465 and resolve remaining disagreements face to face. 466
The Delphi process was predominantly carried out online and was therefore efficient and economically 467 viable in terms of investigator time and funding. Furthermore, it facilitated rapid communication 468 between a global panel of experts. However, the response rate was not 100%, with a total of 18 out of 469 27 experts (62%) responding to the three Delphi rounds. Although early experiments using Delphi 470 suggested that group error was reduced with increased group size (30), more recent studies have found 471 that reliable outcomes can be obtained with a relatively small number of Delphi experts (31). The 472 number of specialised experts in a specific field may be limited. The consistency of expert training may 473 allow small numbers of experts to reliably participate in the generation of valid stable responses. The 474 selection of the panel is therefore extremely important. However, due to the consistency in the number 475 of experts who participated in each round (R1=15, R2=13, R3=14), the possibility of reaching a 476 consensus was conserved. 477
The Delphi panel was not fully representative of the diversity amongst stakeholders of respiratory 478 health, such as healthcare payers or patients. The wide range of opinions gathered could be bolstered 479 with an increase in the variety of stakeholders. 480
The design of the Delphi process, which involved the gathering of opinions from a group of experts, 481 dilutes the opinion of a single expert. Thus, bias is decreased and diversity within the expert panel is 482 maximised, which in turn decreases the possibility of overlooking the obvious facets of the questions. 483
Despite the incomplete response rate and possible changes in experts participating in each round, the 484 final results covered a wide range of areas where consensus was achieved. It is important to remember 485 that the Delphi method is a tool to be used in conjunction with other processes which can be used to 486 answer a wide range of research questions. 487
It is beyond the scope of this study to investigate the reasons behind the convergent or divergent views 488 of the panel. However, these reasons should be explored next to further validate the methodology of a 489
Delphi exercise. 490
Conclusion 491
Using the Delphi process to gain an international consensus among severe asthma experts across sixteen 492 countries, a standardised framework was developed to describe patients with severe asthma, which may 493 help to define a link between best practices and improved outcomes. These questions cover a 494 comprehensive range of variables from patient demographics, diagnostics, patient-or physician-495 reported outcomes and treatment management plans. Collecting a minimum necessary amount of real-496 life data on a severe asthma patient will not only enhance the quality of patient care, but also ensure the 497 sustainability of ISAR as an international registry given that there are often limited resources available 498 for data collection. This is the first attempt to develop such a registry on a global scale within the setting 499 of severe asthma. The main goal of this effort is to standardise data collection to enable pooling of 500 multiple data sources and assist in clinical decision-making for healthcare professionals around the 501 world. The next step is to enrol patients and collect data that will allow gaps in diagnosis and treatment 502 to be identified, and solutions to be found, which will help bridge these gaps and thus bring us one step 503 closer to controlling severe asthma. 504 
Management Plan
Other factors contributing to severe asthma symptoms 2 Current Clinical Management Plan 3 1 "Evidence of poor adherence": This variable has the response options: "No", "Yes: Subjective measure" and "Yes: Objective measure" Poor Adherence to Treatment can be indicated by selecting either (a) or (b): (a) Subjective measure (e.g. Clinical Impression, self-ending): Opinion of a medical personnel for poor adherence to asthma medication therapy or patient self-report • For example 32 . i. Impression of "Non-persistence": Patient stops taking medication.
ii. Impression of "Non-implementation": Patient does not take medication as prescribed. (b) Objective measure (e.g. Prescription Records, electronic monitoring): Evidenced by medical records detailing asthma medication prescriptions being issued and inadequately filled or electronic monitoring obtained by smart inhalers patterns.
• For example: i. Medication Possession Ratio (MPR)= (Sum of days' supply for all fills/Number of days) X 100% <80% threshold 2 "Other factors contributing to severe asthma symptoms": This variable calls for a trained clinician's perception or opinion on any other external factors (if any) that could contribute to the severe asthma symptoms of the patient.
• 
